secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2026-08-03T12:11:28+00:00
Accession:  0001730463-26-000112
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus raises FY2026 AUCATZYL revenue guidance to $140-150M, secures up to $250M credit facility
--------------------------------------------------------------------------------

- Preliminary Q2 2026 AUCATZYL net product revenue ~$45M, up ~70% QoQ and >100% YoY.
- FY2026 net product revenue guidance raised to $140-150M from $120-135M.
- Gross margin improved to ~35% in H1 2026 from negative ~20% in H2 2025.
- Entered five-year interest-only credit facility with Perceptive Advisors for up to $250M; initial $75M funded.
- Cash runway extended into Q2 2028; additional $150M available upon revenue milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000112/0001730463-26-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000112/autl-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001730463-26-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer